Ionis’s bepirovirsen (Hibsago) is now FDA-approved for chronic hepatitis B. The six-month treatment achieved functional cure in up to 26% of patients, far above standard care.
MediciNova fell after mixed Phase 2 data for MN-001. HDL rose, but week-24 liver fat and triglycerides missed significance in 40 patients.
Roche-Ionis sefaxersen beat placebo on proteinuria at week 37 in IgAN Phase 3. Monthly shot enters crowded market vs Novartis Fabhalta.
BMO cut Amgen to Market Perform on valuation after a 34% YTD rally. A Novartis Lp(a) trial miss also raises questions for Amgen’s olpasiran.
Novartis and Ionis said pelacarsen lowered Lp(a) but failed to cut heart attacks, strokes or deaths in a Phase 3 trial of 8,323 patients.
Eplontersen failed to reduce heart events in 1,432 ATTR-CM patients. Results raise questions on silencer-plus-stabilizer use and for Alnylam’s pipeline.
